This inventor holds 4 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Glucox Biotech Ab. Active years: 2017-2025.
Company Filing History:
Years Active: 2017-2025
Title: The Innovations of Erik Walum
Introduction
Erik Walum is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific enzymatic activities. With a total of 4 patents to his name, Walum's work is recognized for its potential therapeutic applications.
Latest Patents
Among his latest patents, Walum has developed sulfonamide derivatives that exhibit selective Nox inhibiting activity. These compounds are described by a specific formula and are useful in therapy for treating conditions associated with nicotinamide adenine dinucleotide phosphate oxidase 4 or 2 (Nox4 or Nox2) activity. Additionally, he has patented a pharmaceutical composition that includes these compounds, further emphasizing their importance in medical treatments. Another significant patent involves compounds designed for the treatment of conditions associated with NADPH oxidase, showcasing his innovative approach to addressing complex health issues.
Career Highlights
Erik Walum is currently associated with Glucox Biotech AB, where he continues to push the boundaries of pharmaceutical research. His work is characterized by a commitment to developing effective treatments that can improve patient outcomes.
Collaborations
Walum collaborates with esteemed colleagues such as Per Wikström and Mona Wilcke, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Erik Walum's contributions to the field of pharmaceuticals through his patents and collaborative efforts highlight his role as a significant inventor. His work continues to pave the way for advancements in medical therapies.